Richard Jenner
@reggenomics.bsky.social
44 followers 640 following 9 posts
Professor of Molecular Biology Head of Department of Cancer Biology and Pathology University College London
Posts Media Videos Starter Packs
reggenomics.bsky.social
Interested in applying your molecular biology skills to improve tumour #immunotherapy?

@cruk-cityoflondon.bsky.social #PhD studentship available in my lab @ucl.ac.uk in collaboration with @diunguyenvnuk.bsky.social @qmbci.bsky.social

For more information and to apply: colcc.ac.uk/phd-students...
reggenomics.bsky.social
This work reveals mechanisms that regulate CD4+ TCTX function in tumours and highlights the potential therapeutic utility of targeting post-transcriptional regulatory pathways in T cells for the treatment of cancer. 8/8
reggenomics.bsky.social
Constitutive expression of Zfp36l1 in T cells nullified anti-tumour responses while knocking out Zfp36l1 and its paralogue Zfp36 released the block to GzmB protein production and promoted tumour control. 7/8
reggenomics.bsky.social
We found that the RNA binding proteins ZFP36L1 and ZFP36 block GzmB protein production and that Zfp36l1 must be downregulated for the therapeutic effects of anti-CTLA-4 and anti-LAG-3 plus anti-PD-1 treatments. 6/8
reggenomics.bsky.social
We characterised this poised TCTX state, finding CD4+ T cells differentiate into poised TCTX in response to type I interferon in a manner dependent on Blimp-1 and antagonised by Bcl6. But what blocks GzmB protein production? 5/8
reggenomics.bsky.social
We instead found that cytotoxic CD4+ T cells (TCTX) are already present in untreated tumours, but in a poised state in which GzmB and other effector genes are transcribed but not translated. 4/8
reggenomics.bsky.social
The Quezada lab has previously shown that CD4+ T cells gain cytotoxicity in response to anti-CTLA4 therapy and can drive tumour regression. We used scRNA-seq to identify the gene expression changes that underly this activity but surprisingly found very few genes change… 3/8
reggenomics.bsky.social
In addition to their well characterized helper function, tumour-infiltrating CD4+ T cells can also acquire cytotoxic activity. These cells hold promise as a therapeutic target but how their activity is regulated remains poorly understood. 2/8